Holen Sie sich die Stockscreener-App
0.8611
13.75%
0.1041
Handel nachbörslich:
.90
0.0389
+4.52%
Schlusskurs vom Vortag:
$0.757
Offen:
$0.782
24-Stunden-Volumen:
5.50M
Relative Volume:
2.25
Marktkapitalisierung:
$140.34M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-111.13M
KGV:
-0.6523
EPS:
-1.32
Netto-Cashflow:
$-91.53M
1W Leistung:
+27.65%
1M Leistung:
+26.04%
6M Leistung:
-9.08%
1J Leistung:
-71.77%
1-Tages-Spanne:
$0.782
$0.90
1-Wochen-Bereich:
$0.6459
$0.90
52-Wochen-Spanne:
$0.36
$4.01
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Firmenname
Tenaya Therapeutics Inc
Sektor
Branche
Telefon
415-865-2066
Adresse
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Vergleichen Sie TNYA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.8611 | 123.37M | 0 | -111.13M | -91.53M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-10 | Eingeleitet | William Blair | Outperform |
| 2023-11-30 | Eingeleitet | Leerink Partners | Outperform |
| 2022-06-15 | Eingeleitet | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Aktie (TNYA) Neueste Nachrichten
Can Tenaya Therapeutics Inc. reach all time highs this yearTop Stocks for Quick Doubling - kangso.co.kr
A Quick Look at Today's Ratings for Tenaya Therapeutics(TNYA.US), With a Forecast Between $3 to $5 - 富途牛牛
Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
Heart Disease Cure? Tenaya CEO Reveals Latest Therapeutic Developments at Major Growth Conference - Stock Titan
Strong Financial Position and Promising Clinical Progress Drive Buy Rating for Tenaya Therapeutics - TipRanks
Tenaya Therapeutics shares rise 6.67% premarket after positive safety reviews for TN-201 and TN-401 gene therapy trials. - AInvest
Tenaya Therapeutics Posts Smaller Losses And Advances Gene Trials - Finimize
Tenaya (TNYA) Q2 Loss Narrows 59% - The Globe and Mail
Tenaya Therapeutics reports Q2 EPS (14c), consensus (19c) - TipRanks
Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Tenaya's Gene Therapies Clear Key Safety Hurdles: Q4 Data Readouts Coming for Heart Disease Treatments - Stock Titan
What are the technical indicators suggesting about Tenaya Therapeutics Inc.Achieve consistent profits with proven methods - Jammu Links News
What analysts say about Tenaya Therapeutics Inc. stockPhenomenal wealth increase - Jammu Links News
Why is Tenaya Therapeutics Inc. stock attracting strong analyst attentionCapitalize on fast-moving stock opportunities - Jammu Links News
How strong is Tenaya Therapeutics Inc. company’s balance sheetMaximize your gains with professional insights - Jammu Links News
Does Tenaya Therapeutics Inc. stock perform well during market downturnsMarket-beating returns - Jammu Links News
What are the latest earnings results for Tenaya Therapeutics Inc.Market-leading capital gains - Jammu Links News
What is Tenaya Therapeutics Inc. company’s growth strategyCapitalize on market shifts before others do - Jammu Links News
What makes Tenaya Therapeutics Inc. stock price move sharplyMaximize gains with timely market signals - Jammu Links News
What is the dividend policy of Tenaya Therapeutics Inc. stockBoost your wealth with consistent growth stocks - Jammu Links News
How sentiment analysis helps forecast Tenaya Therapeutics Inc.ROI Focused Setup Screener With Exit Markers - Newser
Can Tenaya Therapeutics Inc. hit a new high this monthMarket Opportunity Tracker for Swing Traders - Newser
Is Tenaya Therapeutics Inc. stock bottoming outVolume Confirmed Setup with Entry Confidence - Newser
How to read the order book for Tenaya Therapeutics Inc.Free Consistent Profit Pattern Recognition Tools - Newser
Advanced analytics toolkit walkthrough for Tenaya Therapeutics Inc.Technical Confirmation System with Signal Alerts - Newser
How does Tenaya Therapeutics Inc. generate profit in a changing economyChart Pattern Strategy To Watch Now - Jammu Links News
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Rating of “Buy” from Analysts - Defense World
Using economic indicators to assess Tenaya Therapeutics Inc. potentialReal Market Tracker with Price Action Tools - Newser
Will Tenaya Therapeutics Inc. stock go up soonFundamental Forecast for Undervalued Stocks - Newser
What institutions are buying Tenaya Therapeutics Inc. stock nowFundamental Forecast for Undervalued Stocks - Newser
Intrinsic Value of Tenaya Therapeutics Inc. Stock: Is It Undervalued or OvervaluedDaily Breakout List with Smart Filters - Newser
Kalaris Therapeutics shares rise 1.49% intraday after Tenaya Therapeutics, Inc. received positive safety endorsements for its cardiovascular gene therapy clinical trials. - AInvest
Published on: 2025-07-30 22:05:21 - metal.it
Tenaya Receives Positive Safety Reviews from Independent - GlobeNewswire
Tenaya Therapeutics stock rises after positive safety reviews for heart gene therapies By Investing.com - Investing.com South Africa
Tenaya Therapeutics stock rises after positive safety reviews for heart gene therapies - Investing.com Nigeria
Gene Therapy's Cardiovascular Revolution: Why Tenaya Therapeutics Is a High-Conviction Bet in 2025 - AInvest
Tenaya completes enrollment in both dose cohorts for HCM gene therapy - Investing.com
Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed - The Manila Times
Breakthrough: Tenaya's Dual Heart Disease Gene Therapies Pass Major Safety Milestone - Stock Titan
How Resilient Is Tenaya Therapeutics Inc. Stock During Economic DownturnsEarly Buy Opportunity with Chart Triggers - Newser
Will earnings trigger a reversal in Tenaya Therapeutics Inc.Real-Time AI Entry Forecast Generator - Newser
What analysts say about Tenaya Therapeutics Inc. stock outlookEntry Optimization Tool with Screener Logic - Newser
Finanzdaten der Tenaya Therapeutics Inc-Aktie (TNYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):